Japan Issues Development List For Unapproved Indications; Kyowa Hakko, BMS And Sanofi Lead Requests
This article was originally published in PharmAsia News
Executive Summary
MHLW solicited requests from medical associations for compounds with unapproved indications in Japan that would meet unmet medical needs.
You may also be interested in...
FDA Approves Drug For Rare Disease Without Clinical Trial
Orphan Europe's Carbaglu approval was based on a retrospective analysis of case studies - but FDA has said it should not be viewed as a precedent.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.